The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Inmazeb
atoltivimab, maftivimab, and odesivimab-ebgn · ATOLTIVIMAB 483.3 mg/14.5mL; MAFTIVIMAB 483.3 mg/14.5mL; ODESIVIMAB 483.3 mg/14.5mL · Injection, Solution · Intravenous · Regeneron Pharmaceuticals, Inc.
NDC 61755-0019-01 · 1 VIAL, SINGLE-DOSE in 1 CARTON / 14.5 mL in 1 VIAL, SINGLE-DOSE · BLA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- analysis · api manufacture
- Regeneron Pharmaceuticals, Inc.United Statesanalysis
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- BLA761169
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of atoltivimab, maftivimab, and odesivimab-ebgn (Injection, Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | ATOLTIVIMAB 241.7 mg/14.5mL; MAFTIVIMAB 241.7 mg/14.5mL; ODESIVIMAB 241.7 mg/14.5mL | Jul 15, 2026 | Sep 2, 2026 |
| Regeneron Pharmaceuticals, Inc. | ATOLTIVIMAB 483.3 mg/14.5mL; MAFTIVIMAB 483.3 mg/14.5mL; ODESIVIMAB 483.3 mg/14.5mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Inmazeb — NDC 61755-0019-01," retrieved September 3, 2026, https://drugdashboards.com/drug/61755001901.
Free to cite with attribution — see how the data is put together.